JP2021183609A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021183609A5 JP2021183609A5 JP2021120820A JP2021120820A JP2021183609A5 JP 2021183609 A5 JP2021183609 A5 JP 2021183609A5 JP 2021120820 A JP2021120820 A JP 2021120820A JP 2021120820 A JP2021120820 A JP 2021120820A JP 2021183609 A5 JP2021183609 A5 JP 2021183609A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- halogen
- alkenyl
- occurrence
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023115451A JP7797769B2 (ja) | 2016-03-16 | 2023-07-13 | メニン－ｍｌｌの置換された阻害剤及びその使用方法 |
| JP2025160630A JP2026009955A (ja) | 2016-03-16 | 2025-09-26 | メニン－ｍｌｌの置換された阻害剤及びその使用方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662309372P | 2016-03-16 | 2016-03-16 | |
| US62/309,372 | 2016-03-16 | ||
| US201662334369P | 2016-05-10 | 2016-05-10 | |
| US62/334,369 | 2016-05-10 | ||
| US201662431389P | 2016-12-07 | 2016-12-07 | |
| US62/431,389 | 2016-12-07 | ||
| US201762446640P | 2017-01-16 | 2017-01-16 | |
| US62/446,640 | 2017-01-16 | ||
| JP2018544324A JP6919977B2 (ja) | 2016-03-16 | 2017-03-15 | メニン−ｍｌｌの置換された阻害剤及びその使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018544324A Division JP6919977B2 (ja) | 2016-03-16 | 2017-03-15 | メニン−ｍｌｌの置換された阻害剤及びその使用方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023115451A Division JP7797769B2 (ja) | 2016-03-16 | 2023-07-13 | メニン－ｍｌｌの置換された阻害剤及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021183609A JP2021183609A (ja) | 2021-12-02 |
| JP2021183609A5 true JP2021183609A5 (enExample) | 2022-04-21 |
| JP7712129B2 JP7712129B2 (ja) | 2025-07-23 |
Family
ID=59851028
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018544324A Active JP6919977B2 (ja) | 2016-03-16 | 2017-03-15 | メニン−ｍｌｌの置換された阻害剤及びその使用方法 |
| JP2021120820A Active JP7712129B2 (ja) | 2016-03-16 | 2021-07-21 | メニン－ｍｌｌの置換された阻害剤及びその使用方法 |
| JP2023115451A Active JP7797769B2 (ja) | 2016-03-16 | 2023-07-13 | メニン－ｍｌｌの置換された阻害剤及びその使用方法 |
| JP2025160630A Pending JP2026009955A (ja) | 2016-03-16 | 2025-09-26 | メニン－ｍｌｌの置換された阻害剤及びその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018544324A Active JP6919977B2 (ja) | 2016-03-16 | 2017-03-15 | メニン−ｍｌｌの置換された阻害剤及びその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023115451A Active JP7797769B2 (ja) | 2016-03-16 | 2023-07-13 | メニン－ｍｌｌの置換された阻害剤及びその使用方法 |
| JP2025160630A Pending JP2026009955A (ja) | 2016-03-16 | 2025-09-26 | メニン－ｍｌｌの置換された阻害剤及びその使用方法 |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US10781218B2 (enExample) |
| EP (2) | EP3429591B1 (enExample) |
| JP (4) | JP6919977B2 (enExample) |
| KR (1) | KR102419531B1 (enExample) |
| CN (2) | CN114539284A (enExample) |
| AU (1) | AU2017232516B2 (enExample) |
| BR (1) | BR112018068703B1 (enExample) |
| CA (1) | CA3015847C (enExample) |
| CY (1) | CY1126066T1 (enExample) |
| DK (1) | DK3429591T3 (enExample) |
| ES (1) | ES2947636T3 (enExample) |
| FI (1) | FI3429591T3 (enExample) |
| HR (1) | HRP20230537T1 (enExample) |
| HU (1) | HUE061989T2 (enExample) |
| IL (1) | IL261606B (enExample) |
| LT (1) | LT3429591T (enExample) |
| MD (1) | MD3429591T2 (enExample) |
| MX (1) | MX388839B (enExample) |
| MY (1) | MY201450A (enExample) |
| PH (1) | PH12018501952A1 (enExample) |
| PL (1) | PL3429591T3 (enExample) |
| PT (1) | PT3429591T (enExample) |
| RS (1) | RS64261B1 (enExample) |
| SG (1) | SG11201807982UA (enExample) |
| SI (1) | SI3429591T1 (enExample) |
| SM (1) | SMT202300273T1 (enExample) |
| TW (1) | TWI747889B (enExample) |
| WO (1) | WO2017161028A1 (enExample) |
| ZA (1) | ZA202310395B (enExample) |
Families Citing this family (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201802911RA (en) | 2013-03-15 | 2018-05-30 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
| EA202092627A1 (ru) | 2013-11-18 | 2021-09-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| USRE49687E1 (en) | 2014-09-09 | 2023-10-10 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| HK1246593A1 (zh) | 2015-06-04 | 2018-09-14 | Kura Oncology, Inc. | 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物 |
| TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物 |
| GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
| JP6910359B2 (ja) | 2016-01-22 | 2021-07-28 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｎｉｋ阻害剤としての新たな置換されたシアノインドリン誘導体 |
| KR102720461B1 (ko) | 2016-01-22 | 2024-10-21 | 잔센파마슈티카엔.브이. | Nik 억제제로서의 신규 6원 헤테로방향족 치환된 시아노인돌린 유도체 |
| PL3429591T3 (pl) | 2016-03-16 | 2023-07-17 | Kura Oncology, Inc. | Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania |
| PH12018501955B1 (en) | 2016-03-16 | 2024-01-24 | Kura Oncology Inc | Bridged bicyclic inhibitors of menin-mll and methods of use |
| JP6991585B2 (ja) | 2016-05-02 | 2022-01-12 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | メニン阻害剤としてのピペリジン |
| ES2805976T3 (es) | 2016-06-30 | 2021-02-16 | Janssen Pharmaceutica Nv | Derivados heteroaromáticos en calidad de inhibidores de NIK |
| WO2018002219A1 (en) | 2016-06-30 | 2018-01-04 | Janssen Pharmaceutica Nv | Cyanoindoline derivatives as nik inhibitors |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| CR20190119A (es) | 2016-09-09 | 2019-06-03 | Novartis Ag | Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje |
| CA3033020A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Fused bicyclic inhibitors of menin-mll interaction |
| EP3512857B1 (en) | 2016-09-14 | 2021-02-24 | Janssen Pharmaceutica NV | Spiro bicyclic inhibitors of menin-mll interaction |
| US12084462B2 (en) | 2016-09-14 | 2024-09-10 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| EP3538101B1 (en) | 2016-11-14 | 2024-06-19 | Virginia Commonwealth University | Inhibitors of cancer and/or metastasis |
| WO2018109088A1 (en) | 2016-12-15 | 2018-06-21 | Janssen Pharmaceutica Nv | Azepane inhibitors of menin-mll interaction |
| CN110248946B (zh) | 2016-12-15 | 2023-05-23 | 詹森药业有限公司 | Menin-MLL相互作用的氮杂环庚烷抑制剂 |
| WO2018175746A1 (en) * | 2017-03-24 | 2018-09-27 | Kura Oncology, Inc. | Methods for treating hematological malignancies and ewing's sarcoma |
| MX2019011412A (es) | 2017-03-31 | 2020-02-07 | Univ Michigan Regents | Piperidinas como inhibidores de menina covalentes. |
| WO2018226976A1 (en) | 2017-06-08 | 2018-12-13 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| EP4467143B1 (en) | 2017-07-10 | 2026-03-11 | Celgene Corporation | Method for preparing 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile |
| AU2018300150A1 (en) | 2017-07-11 | 2020-01-30 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| EP3684361A4 (en) | 2017-09-20 | 2021-09-08 | Kura Oncology, Inc. | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHOD OF USING |
| AU2018346597B2 (en) | 2017-10-06 | 2023-07-13 | Forma Therapeutics, Inc. | Inhibiting Ubiquitin Specific Peptidase 30 |
| DK3786160T3 (da) | 2017-10-27 | 2022-08-22 | Boehringer Ingelheim Int | Pyridinderivater og terapeutiske anvendelser deraf som trpc6-inhibitorer |
| WO2019120212A1 (zh) * | 2017-12-19 | 2019-06-27 | 基石药业（苏州）有限公司 | Ido抑制剂 |
| JP7307729B2 (ja) | 2017-12-20 | 2023-07-12 | ヤンセン ファーマシューティカ エヌ．ベー． | メニン－ｍｌｌ相互作用のエキソ－アザスピロ阻害剤 |
| US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖ複製阻害剤としての置換ピロリジン化合物 |
| TWI877770B (zh) | 2018-02-27 | 2025-03-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶 |
| CN110204552B (zh) * | 2018-02-28 | 2021-08-17 | 中国科学院上海药物研究所 | 一类噻吩并[3,2-d]嘧啶衍生物、其制备方法、药物组合物与用途 |
| EP4566612A3 (en) | 2018-03-09 | 2025-08-20 | Recurium IP Holdings, LLC | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
| EP3765459A1 (en) | 2018-03-13 | 2021-01-20 | Shire Human Genetic Therapies, Inc. | Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof |
| US11325921B2 (en) | 2018-03-30 | 2022-05-10 | Sumitomo Dainippon Pharma Co., Ltd. | Optically active crosslinked cyclic secondary amine derivative |
| TW202012414A (zh) | 2018-04-12 | 2020-04-01 | 美商拓臻股份有限公司 | 三環ask1抑制劑 |
| FI3784663T3 (fi) | 2018-04-23 | 2023-10-06 | Celgene Corp | Substituoituja 4-aminoisoindoliini-1,3-dioniyhdisteitä ja niiden käyttö lymfooman hoitamiseksi |
| JP7449242B2 (ja) | 2018-05-17 | 2024-03-13 | フォーマ セラピューティクス，インコーポレイテッド | ユビキチン特異的ペプチダーゼ３０（ｕｓｐ３０）阻害剤として有用な縮合二環化合物 |
| EP3810610A1 (en) | 2018-05-18 | 2021-04-28 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| US10934279B2 (en) | 2018-06-13 | 2021-03-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
| WO2020010197A1 (en) | 2018-07-05 | 2020-01-09 | Incyte Corporation | Fused pyrazine derivatives as a2a / a2b inhibitors |
| CR20210175A (es) | 2018-09-18 | 2021-06-01 | Nikang Therapeutics Inc | Derivados de anillo tricíclico condensado como inhibidores de la fosfatasa de homología a src 2 (shp2) |
| JP2022503792A (ja) * | 2018-09-26 | 2022-01-12 | クラ オンコロジー，インク． | メニン阻害剤を用いた血液悪性腫瘍の処置 |
| JP7530889B2 (ja) | 2018-10-05 | 2024-08-08 | フォーマ セラピューティクス，インコーポレイテッド | ユビキチン特異的プロテアーゼ３０（ｕｓｐ３０）阻害剤として作用する縮合ピロリン |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| MA54555A (fr) | 2018-11-22 | 2021-09-29 | Qilu Regor Therapeutics Inc | Agonistes de glp-1r et leurs utilisations |
| AU2019395201A1 (en) | 2018-12-06 | 2021-05-20 | Daiichi Sankyo Company, Limited | Cycloalkane-1,3-diamine derivative |
| SG11202106304RA (en) | 2018-12-31 | 2021-07-29 | Biomea Fusion Llc | Irreversible inhibitors of menin-mll interaction |
| US11174263B2 (en) | 2018-12-31 | 2021-11-16 | Biomea Fusion, Inc. | Inhibitors of menin-MLL interaction |
| WO2020146682A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| US12440481B2 (en) | 2019-01-10 | 2025-10-14 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
| MX2021008661A (es) | 2019-01-18 | 2021-08-19 | Astrazeneca Ab | Inhibidores de la pcsk9 y metodos de uso de los mismos. |
| BR112021013807A2 (pt) | 2019-01-18 | 2021-11-30 | Astrazeneca Ab | Inibidores de pcsk9 e seus métodos de uso |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
| TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| EP3953344A4 (en) | 2019-04-12 | 2023-08-09 | Qilu Regor Therapeutics Inc. | GLP-IR AGONISTS AND THEIR USES |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
| EP3994132A1 (en) | 2019-07-03 | 2022-05-11 | Sumitomo Dainippon Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof |
| CA3150681A1 (en) | 2019-08-14 | 2021-02-18 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| DK4031547T3 (da) | 2019-09-18 | 2024-09-09 | Takeda Pharmaceuticals Co | Plasmakallikreininhibitorer og anvendelser deraf |
| EP4031245A1 (en) | 2019-09-18 | 2022-07-27 | Takeda Pharmaceutical Company Limited | Heteroaryl plasma kallikrein inhibitors |
| US11851426B2 (en) | 2019-10-11 | 2023-12-26 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| EP4048664A1 (en) | 2019-10-25 | 2022-08-31 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| BR112022010924A2 (pt) | 2019-12-06 | 2022-09-06 | Vertex Pharma | Tetra-hidrofuranos substituídos como moduladores de canais de sódio |
| TW202525813A (zh) | 2019-12-19 | 2025-07-01 | 比利時商健生藥品公司 | 經取代之直鏈螺環接衍生物 |
| MX2022007969A (es) | 2019-12-23 | 2022-12-13 | Blueprint Medicines Corp | Inhibidores de egfr. |
| US12441707B2 (en) | 2019-12-30 | 2025-10-14 | Tyra Biosciences, Inc. | Indazole compounds |
| CN115210229A (zh) | 2020-01-03 | 2022-10-18 | 博格有限责任公司 | 多环酰胺作为治疗癌症的ube2k调节剂 |
| ES3016132T3 (en) | 2020-01-29 | 2025-05-08 | Gilead Sciences Inc | Glp-1r modulating compounds |
| KR20250133471A (ko) | 2020-02-18 | 2025-09-05 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 화합물 |
| TWI775313B (zh) | 2020-02-18 | 2022-08-21 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI883391B (zh) | 2020-02-18 | 2025-05-11 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| CN111297863B (zh) * | 2020-03-30 | 2021-06-25 | 四川大学华西医院 | menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用 |
| BR112022019517A2 (pt) | 2020-03-30 | 2022-12-06 | Hutchison Medipharma Ltd | Compostos de amida e usos dos mesmos |
| ES3054109T3 (en) | 2020-05-15 | 2026-01-29 | Algen Biotechnologies Inc | Certain chemical compositions and methods of use thereof |
| EP4232020A4 (en) * | 2020-10-21 | 2024-08-07 | Kura Oncology, Inc. | Treatment of hematological malignancies with inhibitors of menin |
| CN114516873A (zh) * | 2020-11-18 | 2022-05-20 | 苏州优理生物医药科技有限公司 | 一种螺环类化合物、包含其药物组合物及其应用 |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| KR20230152654A (ko) | 2020-12-30 | 2023-11-03 | 타이라 바이오사이언시스, 인크. | 키나아제 억제제로서의 인다졸 화합물 |
| CA3208361A1 (en) | 2021-02-19 | 2022-08-25 | Anjali Pandey | Tyk2 inhibitors and uses thereof |
| EP4294806A1 (en) | 2021-02-19 | 2023-12-27 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| AU2022222470A1 (en) | 2021-02-19 | 2023-09-21 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| WO2022192428A1 (en) | 2021-03-11 | 2022-09-15 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| EP4304712A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| WO2022208454A1 (en) | 2021-04-02 | 2022-10-06 | Bridge Biotherapeutics, Inc. | N2-phenylpyrimidine-2,4-diamine compounds, and preparation methods and methods of use thereof |
| CA3216162A1 (en) | 2021-04-16 | 2022-10-20 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
| IL306110A (en) | 2021-04-21 | 2023-11-01 | Gilead Sciences Inc | Carboxy-benzimidazole glp-1r modulating compounds |
| CA3215379A1 (en) | 2021-05-08 | 2022-11-17 | Olivier Alexis Georges Querolle | Substituted spiro derivatives |
| US20240417405A1 (en) | 2021-05-08 | 2024-12-19 | Janssen Pharmaceutica Nv | Substituted Spiro Derivatives |
| IL308862A (en) | 2021-06-01 | 2024-01-01 | Janssen Pharmaceutica Nv | Altered phenyl-1H-pyrrolo[3,2-c]pyridine histories |
| JP2024521902A (ja) | 2021-06-03 | 2024-06-04 | ヤンセン ファーマシューティカ エヌ．ベー． | スピロ環状アミンで置換されたピリダジン又は１，２，４－トリアジン |
| WO2022253309A1 (zh) * | 2021-06-03 | 2022-12-08 | 首药控股(北京)股份有限公司 | 取代的杂环化合物及其应用 |
| SMT202500481T1 (it) | 2021-06-04 | 2026-01-12 | Vertex Pharma | N-(idrossialchil(etero)aril)tetraidrofuran carbossammidi come modulatori di canali del sodio |
| WO2022262796A1 (en) | 2021-06-17 | 2022-12-22 | Janssen Pharmaceutica Nv | (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-m ethylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| CN115515958B (zh) * | 2021-08-04 | 2023-09-29 | 成都苑东生物制药股份有限公司 | 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途 |
| WO2023011446A1 (zh) * | 2021-08-04 | 2023-02-09 | 成都苑东生物制药股份有限公司 | 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途 |
| TW202320796A (zh) | 2021-08-11 | 2023-06-01 | 美商拜歐米富士恩股份有限公司 | 用於糖尿病的menin-mll相互作用之共價抑制劑 |
| AU2022328698B2 (en) | 2021-08-18 | 2025-02-20 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| US12018032B2 (en) | 2021-08-20 | 2024-06-25 | Biomea Fusion, Inc. | Crystalline forms of N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide as an irreversible inhibitor of menin-MLL interaction |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| CN118234497A (zh) * | 2021-12-15 | 2024-06-21 | 丹娜-法伯癌症研究所 | 通过破坏menin-mll表观遗传复合体靶向治疗胃肠道间质瘤(gist) |
| US20250152591A1 (en) * | 2022-02-04 | 2025-05-15 | Kura Oncology, Inc. | Treatment of hematological malignancies with menin inhibitors and p-glycoprotein inhibitors |
| PL4514782T3 (pl) | 2022-05-19 | 2026-02-23 | Astrazeneca Ab | Związki amidoheteroaromatyczne przydatne w leczeniu chorób wątroby |
| CN117069719A (zh) * | 2022-08-17 | 2023-11-17 | 烨辉医药科技(上海)有限公司 | 二氮杂螺环-哒嗪化合物及其用途 |
| IL319572A (en) | 2022-09-26 | 2025-05-01 | Alterome Therapeutics Inc | AKT1 modulators |
| CN120529900A (zh) | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
| WO2024155710A1 (en) | 2023-01-18 | 2024-07-25 | Biomea Fusion, Inc. | Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6- yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2-pyridinecarboxamide as a covalent inhibitor of menin-mll interaction |
| IL325861A (en) | 2023-07-17 | 2026-03-01 | Kura Oncology Inc | Crystalline forms of menin inhibitor |
| TW202517650A (zh) | 2023-07-17 | 2025-05-01 | 美商庫拉腫瘤技術股份有限公司 | 包含ｍｅｎｉｎ抑制劑之醫藥組合物 |
Family Cites Families (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5861A (en) | 1848-10-17 | Locking umbrella and parasol | ||
| US5863A (en) | 1848-10-17 | Matthias p | ||
| US510A (en) | 1837-12-07 | soeel | ||
| US949A (en) | 1838-09-27 | Improvement in roller cotton-gins for ginning long-staple and other kinds of cotton | ||
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| DE4239169A1 (de) | 1992-11-21 | 1994-05-26 | Merck Patent Gmbh | Cyclobutan - Benzol - Derivate |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| ES2153031T4 (es) | 1995-04-20 | 2001-05-16 | Pfizer | Derivados del acido arilsulfonil hidroxamico como inhibidores de mmp y tnf. |
| ATE225343T1 (de) | 1995-12-20 | 2002-10-15 | Hoffmann La Roche | Matrix-metalloprotease inhibitoren |
| JP3195756B2 (ja) | 1996-07-04 | 2001-08-06 | 公子 吉水 | 潤滑補助体 |
| KR20000067904A (ko) | 1996-07-18 | 2000-11-25 | 디. 제이. 우드, 스피겔 알렌 제이 | 매트릭스 메탈로프로테아제의 포스피네이트계 억제제 |
| KR20000068248A (ko) | 1996-08-23 | 2000-11-25 | 디. 제이. 우드, 스피겔 알렌 제이 | 아릴설포닐아미노 하이드록삼산 유도체 |
| US5866562A (en) | 1996-10-25 | 1999-02-02 | Bayer Aktiengesellschaft | Ring-bridged bis-quinolines |
| JP3338064B2 (ja) | 1997-01-06 | 2002-10-28 | ファイザー・インク | 環状スルホン誘導体 |
| NZ336840A (en) | 1997-02-03 | 2001-01-26 | Pfizer Prod Inc | Arylsulfonylamino hydroxamic acid derivatives useful in the treatment of tumor necrosis factor and matrix metalloproteinase mediated diseases |
| JP2000507975A (ja) | 1997-02-07 | 2000-06-27 | ファイザー・インク | Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用 |
| EP0960098A1 (en) | 1997-02-11 | 1999-12-01 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
| JPH10330377A (ja) | 1997-06-02 | 1998-12-15 | Kyowa Hakko Kogyo Co Ltd | ピペリジン誘導体 |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| US6479487B1 (en) | 1998-02-26 | 2002-11-12 | Aventis Pharmaceuticals Inc. | 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| US20070208087A1 (en) | 2001-11-02 | 2007-09-06 | Sanders Virginia J | Compounds, compositions and methods for the treatment of inflammatory diseases |
| US7074801B1 (en) | 2001-04-26 | 2006-07-11 | Eisai Co., Ltd. | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof |
| MXPA03009925A (es) | 2001-04-30 | 2004-06-30 | Bayer Pharmaceuticals Corp | Nuevas tiofeno [2,3-d]pirimidinas 4-amino-5,6-sustituidas. |
| WO2003022214A2 (en) | 2001-09-06 | 2003-03-20 | Millennium Pharmaceuticals, Inc. | Piperazine and homopiperazine compounds |
| AU2003258662A1 (en) | 2002-10-02 | 2004-04-23 | Merck Patent Gmbh | Use of 4-amino-quinazolines as anti cancer agents |
| WO2004030672A1 (en) | 2002-10-02 | 2004-04-15 | Merck Patent Gmbh | Use of 4 amino-quinazolines as anti cancer agents |
| NZ542236A (en) | 2003-03-31 | 2008-05-30 | Predix Pharmaceuticals Holding | New piperidinylamino-thieno[2,3-d]pyrimidine compounds |
| US7612078B2 (en) | 2003-03-31 | 2009-11-03 | Epix Delaware, Inc. | Piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| US20050222175A1 (en) | 2004-03-31 | 2005-10-06 | Dhanoa Dale S | New piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| EP1663962A4 (en) | 2003-08-22 | 2007-08-22 | Dendreon Corp | COMPOSITIONS AND METHODS FOR TREATING A DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION |
| US20050123906A1 (en) | 2003-11-06 | 2005-06-09 | Rana Tariq M. | Protein modulation |
| US20060025406A1 (en) | 2004-07-06 | 2006-02-02 | Angion Biomedica Corporation | Modulators of hepatocyte growth factor/c- Met activity |
| US7553964B2 (en) | 2005-06-03 | 2009-06-30 | Abbott Laboratories | Cyclobutyl amine derivatives |
| US20060281769A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators |
| US20060281771A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators |
| TW200800225A (en) | 2005-09-02 | 2008-01-01 | Tibotec Pharm Ltd | Benzodiazepines as HCV inhibitors |
| US7744968B2 (en) | 2005-09-19 | 2010-06-29 | Merck Patent Gmbh | Cyclobutane and spiro[3.3]heptane compounds |
| FR2891829A1 (fr) | 2005-10-12 | 2007-04-13 | Sanofi Aventis Sa | Derives de la 4-amino-quinazoline, leur preparation et leur application en therapeutique |
| AR057579A1 (es) | 2005-11-23 | 2007-12-05 | Merck & Co Inc | Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac) |
| US7910595B2 (en) | 2005-12-21 | 2011-03-22 | Abbott Laboratories | Anti-viral compounds |
| CA2651898A1 (en) | 2006-04-07 | 2007-10-18 | Develogen Aktiengesellschaft | Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions |
| EP1903044A1 (en) * | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosine Derivatives as A2A Receptor Agonists |
| US8242078B2 (en) | 2006-10-19 | 2012-08-14 | The University Of Chicago | Therapeutics to inhibit MLL-menin interaction for treating leukemia |
| EP1947103A1 (en) | 2007-01-22 | 2008-07-23 | 4Sc Ag | Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments |
| WO2008099019A1 (en) | 2007-02-16 | 2008-08-21 | Tibotec Pharmaceuticals Ltd. | 6-hydroxy-dibenzodiazepinones useful as hepatitis c virus inhibitors |
| FR2913017A1 (fr) | 2007-02-23 | 2008-08-29 | Cerep Sa | Derives de piperidine et piperazine comme agents anti-neoplasiques ou inhibiteurs de proliferation cellulaire |
| JP5284291B2 (ja) | 2007-03-19 | 2013-09-11 | カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ | 潜在的制癌剤としての新規アントラニル酸誘導体及びその調製方法 |
| WO2008135232A1 (en) | 2007-05-02 | 2008-11-13 | Riccardo Cortese | Use and compositions of purine derivatives for the treatment of proliferative disorders |
| CA2687187A1 (en) | 2007-05-25 | 2008-12-18 | Burnham Institute For Medical Research | Inhibitors of thapsigargin-induced cell death |
| WO2009017838A2 (en) | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
| WO2009064388A2 (en) | 2007-11-09 | 2009-05-22 | Liu Jun O | Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders |
| WO2009086303A2 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| BRPI0912988A2 (pt) | 2008-05-22 | 2019-09-24 | Allergan Inc | compostos bicíclicos tendo atividade no receptor cxcr4. |
| DE102008027574A1 (de) * | 2008-06-10 | 2009-12-17 | Merck Patent Gmbh | Neue Pyrrolidinderivate als MetAP-2 Inhibitoren |
| JP5555236B2 (ja) | 2008-08-25 | 2014-07-23 | アイアールエム・リミテッド・ライアビリティ・カンパニー | ヘッジホッグ経路モジュレーター |
| CN102186479A (zh) | 2008-09-10 | 2011-09-14 | 凯利普西斯公司 | 用于治疗疾病的组胺受体的氨基嘧啶抑制剂 |
| GB0904285D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| TW201038572A (en) | 2009-03-25 | 2010-11-01 | Gruenenthal Gmbh | Substituted spiro-amide compounds |
| AU2010257856A1 (en) | 2009-06-08 | 2011-11-03 | Grünenthal GmbH | Substituted benzimidazoles, benzothiazoles and benzoxazoles |
| WO2010147234A1 (en) | 2009-06-18 | 2010-12-23 | Banyu Pharmaceutical Co.,Ltd. | Diarylamide-spirodiamine derivative |
| WO2011003418A1 (en) | 2009-07-08 | 2011-01-13 | Leo Pharma A/S | Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors |
| EP2459533A4 (en) | 2009-07-30 | 2013-01-16 | Univ Singapore | SMALL MOLECULAR ISOPRENYLCYSTONE CARBOXYL METHYLTRANSFERASE HEMMER WITH POTENTIAL ANTIBODY EFFECT |
| CN102984941B (zh) * | 2009-09-04 | 2016-08-17 | 密执安大学评议会 | 用于治疗白血病的组合物和方法 |
| SG183233A1 (en) | 2010-02-22 | 2012-09-27 | Merck Patent Gmbh | Hetarylaminonaphthyridines |
| KR101541086B1 (ko) | 2010-08-20 | 2015-08-03 | 허치슨 메디파르마 리미티드 | 피롤로피리미딘 화합물 및 그 용도 |
| US9090624B2 (en) | 2011-08-04 | 2015-07-28 | Allergan, Inc. | Aromatic bycyclic derivatives as CXCR4 receptor modulators |
| GB201114212D0 (en) | 2011-08-18 | 2011-10-05 | Ucb Pharma Sa | Therapeutic agents |
| AR090037A1 (es) * | 2011-11-15 | 2014-10-15 | Xention Ltd | Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio |
| CN103833759A (zh) | 2012-11-23 | 2014-06-04 | 华东理工大学 | 作为blk、flt3抑制剂的蝶啶酮衍生物及其应用 |
| GB201217704D0 (en) | 2012-10-03 | 2012-11-14 | Ucb Pharma Sa | Therapeutic agents |
| WO2014164543A1 (en) * | 2013-03-13 | 2014-10-09 | The Regents Of The University Of Michigan | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
| EP2968285A4 (en) | 2013-03-13 | 2016-12-21 | Flatley Discovery Lab | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS |
| US9212180B2 (en) | 2013-06-12 | 2015-12-15 | The Regents Of The University Of Michigan | Menin-MLL inhibitors and methods of use thereof |
| US9650379B2 (en) | 2013-12-12 | 2017-05-16 | Chong Kun Dang Pharmaceutical Corp. | Azaindole derivatives as selective histone deacetylase (HDAC) inhibitors and pharmaceutical compositions comprising the same |
| CN110229142A (zh) | 2014-04-04 | 2019-09-13 | 希洛斯医药品股份有限公司 | 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂 |
| US20170119769A1 (en) | 2014-06-10 | 2017-05-04 | The Trustees Of The University Of Pennsylvania | Scaffolds for inhibitors of menin-mll interactions |
| USRE49687E1 (en) * | 2014-09-09 | 2023-10-10 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| CN105732636B (zh) | 2014-12-30 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物 |
| HK1246593A1 (zh) | 2015-06-04 | 2018-09-14 | Kura Oncology, Inc. | 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物 |
| BR112017028318B1 (pt) | 2015-07-02 | 2024-02-20 | Janssen Sciences Ireland Uc | Composto antibacteriano, seu uso, processo para sua preparação,produto que o contém, composição farmacêutica e combinação |
| AU2016378579A1 (en) | 2015-12-22 | 2018-06-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-MLL interaction |
| AR107354A1 (es) | 2016-01-13 | 2018-04-18 | Bristol Myers Squibb Co | Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock |
| US10869868B2 (en) | 2016-01-26 | 2020-12-22 | Memorial Sloan Kettering Cancer Center | Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia |
| PH12018501955B1 (en) | 2016-03-16 | 2024-01-24 | Kura Oncology Inc | Bridged bicyclic inhibitors of menin-mll and methods of use |
| PL3429591T3 (pl) | 2016-03-16 | 2023-07-17 | Kura Oncology, Inc. | Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania |
| JP6991585B2 (ja) | 2016-05-02 | 2022-01-12 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | メニン阻害剤としてのピペリジン |
| WO2017207387A1 (en) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction |
| WO2017214367A1 (en) | 2016-06-10 | 2017-12-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| WO2018024602A1 (en) | 2016-08-04 | 2018-02-08 | Bayer Aktiengesellschaft | 2,7-diazaspiro[4.4]nonanes |
| CA3033020A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Fused bicyclic inhibitors of menin-mll interaction |
| CA3033239A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-mll interaction |
| AU2017326006B2 (en) | 2016-09-16 | 2021-10-28 | Vitae Pharmaceuticals, LLC. | Inhibitors of the menin-MLL interaction |
| EP3684361A4 (en) | 2017-09-20 | 2021-09-08 | Kura Oncology, Inc. | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHOD OF USING |
-
2017
- 2017-03-15 PL PL17767462.9T patent/PL3429591T3/pl unknown
- 2017-03-15 DK DK17767462.9T patent/DK3429591T3/da active
- 2017-03-15 US US16/082,649 patent/US10781218B2/en active Active
- 2017-03-15 LT LTEPPCT/US2017/022564T patent/LT3429591T/lt unknown
- 2017-03-15 MY MYPI2018001520A patent/MY201450A/en unknown
- 2017-03-15 ES ES17767462T patent/ES2947636T3/es active Active
- 2017-03-15 CN CN202210112927.9A patent/CN114539284A/zh active Pending
- 2017-03-15 SM SM20230273T patent/SMT202300273T1/it unknown
- 2017-03-15 JP JP2018544324A patent/JP6919977B2/ja active Active
- 2017-03-15 WO PCT/US2017/022564 patent/WO2017161028A1/en not_active Ceased
- 2017-03-15 PT PT177674629T patent/PT3429591T/pt unknown
- 2017-03-15 RS RS20230441A patent/RS64261B1/sr unknown
- 2017-03-15 SG SG11201807982UA patent/SG11201807982UA/en unknown
- 2017-03-15 IL IL261606A patent/IL261606B/en unknown
- 2017-03-15 EP EP17767462.9A patent/EP3429591B1/en active Active
- 2017-03-15 FI FIEP17767462.9T patent/FI3429591T3/fi active
- 2017-03-15 BR BR112018068703-0A patent/BR112018068703B1/pt active IP Right Grant
- 2017-03-15 AU AU2017232516A patent/AU2017232516B2/en active Active
- 2017-03-15 MX MX2018011105A patent/MX388839B/es unknown
- 2017-03-15 HR HRP20230537TT patent/HRP20230537T1/hr unknown
- 2017-03-15 KR KR1020187029385A patent/KR102419531B1/ko active Active
- 2017-03-15 CN CN201780030597.6A patent/CN109152784B/zh active Active
- 2017-03-15 MD MDE20190122T patent/MD3429591T2/ro unknown
- 2017-03-15 HU HUE17767462A patent/HUE061989T2/hu unknown
- 2017-03-15 SI SI201731362T patent/SI3429591T1/sl unknown
- 2017-03-15 CA CA3015847A patent/CA3015847C/en active Active
- 2017-03-15 EP EP23151871.3A patent/EP4219449A3/en active Pending
- 2017-03-15 TW TW106108622A patent/TWI747889B/zh active
-
2018
- 2018-09-11 PH PH12018501952A patent/PH12018501952A1/en unknown
-
2020
- 2020-07-30 US US16/944,040 patent/US11673898B2/en active Active
-
2021
- 2021-07-21 JP JP2021120820A patent/JP7712129B2/ja active Active
-
2023
- 2023-06-14 CY CY20231100277T patent/CY1126066T1/el unknown
- 2023-07-13 JP JP2023115451A patent/JP7797769B2/ja active Active
- 2023-11-08 ZA ZA2023/10395A patent/ZA202310395B/en unknown
-
2025
- 2025-01-16 US US19/024,601 patent/US20250320225A1/en active Pending
- 2025-09-26 JP JP2025160630A patent/JP2026009955A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021183609A5 (enExample) | ||
| JP2024520481A5 (enExample) | ||
| JP2019529490A5 (enExample) | ||
| JP2025037925A5 (enExample) | ||
| JP2022551185A5 (enExample) | ||
| RU2405774C9 (ru) | Гетероциклические ингибиторы аспартилпротеазы | |
| JP2008511659A5 (enExample) | ||
| JP2018536648A5 (enExample) | ||
| JP2021523225A5 (enExample) | ||
| JP2014521688A5 (enExample) | ||
| AR067896A1 (es) | Procedimiento para sintetizar compuestos utiles para tratar hepatitis c | |
| JP2013545816A5 (enExample) | ||
| JP2020063289A5 (enExample) | ||
| JP2022538301A5 (enExample) | ||
| JP2019518050A5 (enExample) | ||
| JP2021046404A5 (enExample) | ||
| JP2008518900A5 (enExample) | ||
| JPWO2023106310A5 (enExample) | ||
| JP2014514290A5 (enExample) | ||
| JP2023549494A5 (enExample) | ||
| JP2023164918A5 (enExample) | ||
| JP2021522244A5 (enExample) | ||
| JP2018528942A5 (enExample) | ||
| JPWO2022138968A5 (enExample) | ||
| JP2023537271A5 (enExample) |